Leptin in sepsis: a well-suited biomarker in critically ill patients?

Rodolfo Leonel Bracho-Riquelme*1,2 and Miguel Arturo Reyes-Romero1

See related research by Yousef et al, http://ccforum.com/content/14/2/R33

Abstract
The value of monitoring serum leptin in critically ill patients is important for early diagnosis and differentiation between sepsis and non-infectious systemic inflammatory response syndrome (SIRS). The early diagnosis of sepsis, the identification of its origin, and an adequate therapeutic management are crucial to overcome sepsis-associated mortality. Cytokine levels are the obvious choice as sepsis markers, since cytokines are key mediators of the inflammatory response to sepsis. Leptin, a hormone mainly generated by adipocytes, acts centrally in the hypothalamus to regulate body weight and energy expenditure. There is, however, strong evidence that leptin is also involved in cell-mediated immunity and cytokine crosstalk. The finding that a serum leptin threshold of 38 μg/l can distinguish between sepsis and non-infectious SIRS (sensitivity 91.2%, specificity 85%) is the major finding in the article by Yousef and colleagues (in this issue). Much remains to be learned about the precise mechanisms by which leptin signaling participates in sepsis and non-infectious SIRS. This knowledge will potentially contribute to new therapeutic approaches.

Cytokine levels are the obvious choice as sepsis markers since cytokines are key mediators of the inflammatory response to sepsis. Among the cytokines, TNFα, IL-1, IL-6, IFNγ, IL-10, and IL-13 best characterize the immune dysregulation during sepsis [3].

In 1998 Bornstein and colleagues reported an increase in leptin levels and the loss of the diurnal rhythm of this adipokine in survivors of acute sepsis [4]. They also observed that low leptin and high IL-6 levels indicated an unfavorable prognosis in patients with sepsis syndrome. Owing to contradictory findings in latter reports [5-9], however, the interest in leptin as a sepsis marker waned.

Leptin, a hormone mainly generated by adipocytes, acts centrally in the hypothalamus to regulate body weight and energy expenditure. There is, however, strong evidence that leptin is also involved in cell-mediated immunity and cytokine crosstalk [10].

Yousef and colleagues confirmed a positive correlation between leptin and IL-6 and TNFα in patients with sepsis [11]. The finding that a serum leptin threshold of 38 μg/l can distinguish between sepsis and non-infectious SIRS (sensitivity 91.2%, specificity 85%) is the major finding in the article by Yousef and colleagues (in this issue).

The matter at heart in the early differentiation between sepsis and non-infectious SIRS is the impact on outcome. In patients with surgically confirmed secondary peritonitis, our group found that a serum level of leptin <10 ng/ml was accompanied by a 4.25-fold increase in the risk of death. Our results were limited to moderate to severe peritonitis where the measurement was made 24 hours into the postoperative period (±2 hours) [12]. Since leptin apparently inhibits an excessive or harmful lipopolysaccharide-induced inflammatory reaction to or prevents TNFα-induced lethality in sepsis [13], it would have been interesting if Yousef and colleagues had reported the results of the 11 patients that died in their study group [1]. Our findings [12] concur with those reported by Bornstein and colleagues: an increase is found in leptin serum levels in septic patients, while a low leptin level is associated with a negative outcome [4] – possibly due to the lack of the protective effect of leptin [13].
Yousef and colleagues’ report contributes to our understanding of the regulation of the inflammatory cascade in sepsis [1]. Much remains to be learned about the precise mechanisms by which leptin signaling participates in sepsis and non-infectious SIRS. This knowledge will potentially contribute to new therapeutic approaches.

**Abbreviations**
IFN, interferon; IL, interleukin; SIRS, systemic inflammatory response syndrome; TNF, tumor necrosis factor.

**Author details**
1. Universidad Juárez del Estado de Durango, Facultad de Medicina, División de Estudios de Posgrado e Investigación, Azucenas 157, Fracc. Jardines de Durango, Durango, Dgo. C.P. 34200, México.
2. Hospital General de Durango (SSD), Servicio de Cirugía, Azucenas 157, Fracc. Jardines de Durango, Durango, Dgo. C.P. 34200, México.

**Competing interests**
The authors declare that they have no competing interests.

**Published:** 9 April 2010

**References**
1. Yousef AAE, Amr YM, Suliman GA: The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-α in critically ill patients: a prospective observational study. *Crit Care* 2010, 14:R33.
2. Claus RA, Otto GP, Deigner HP, Bauer M: Approaching clinical reality: markers for monitoring systemic inflammation and sepsis [abstract]. *Curr Mol Med* 2010. [Epub ahead of print]
3. Philippart F, Cavaillon JM, Dinarello C: Inflammatory mediators. In Cavaillon JM, Adrie C, editors. *Sepsis and Non-infectious Systemic Inflammation*. Weinheim: Wiley-Blackwell; 2009:177-204.
4. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negao AB, Gold P, Chrousos GP: Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. *J Clin Endocrinol Metab* 1998, 83:280-283.
5. Torpy DJ, Bornstein SR, Chrousos GP: Leptin and interleukin-6 in sepsis. *Horm Metab Res* 1998, 30:726-729.
6. Arnalich F, López J, Codocoro R, Jiménez M, Madero R, Montiel C: Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock. *J Infect Dis* 1999, 180:908-911.
7. Carlson GL, Saeed M, Little RA, Irving MH: Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis. *Am J Physiol* 1999, 276(4 Pt 1):E658-E662.
8. Papathanassoglou ED, Moynihan JA, Ackerman MH, Mantzoros CS: Serum leptin levels are higher but are not independently associated with severity or mortality in the multiple organ dysfunction/systemic inflammatory response syndrome: a matched case control and a longitudinal study. *Clin Endocrinol (Oxford)* 2001, 54:225-233.
9. Blanco Quiros A, Casado Flores J, Nieto Moro M, Garrote Adriados JA, Arranz Sanz E, Asensio Antón J: Meningococcal sepsis in pediatrics. Parameters associated with poor outcome. *Ann Pediatr (Barc)* 2004, 61:305-313.
10. Haas P, Straub RH, Bedoui S, Nave H: Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. *Regul Pept* 2008, 141:26-34.
11. Maruna P, Gürlich R, Frasko R, Haluzík M: Serum leptin levels in septic men correlate well with C-reactive protein (CRP) and TNF-α but not with BMI. *Physiol Res* 2001, 50:589-594.
12. Bracho-Riquelme RL, Reyes-Romero MA, Pescador N, Flores-García Al: A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis. *Eur Surg Res* 2008, 41:238-244.
13. Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold KR, Grunfeld C: Leptin deficiency enhances sensitivity to endotoxin-induced lethality. *Am J Physiol* 1999, 276(6 Pt 1):R136-R142.

**Cite this article as:** Bracho-Riquelme RL, Reyes-Romero MA: Leptin in sepsis: a well-suited biomarker in critically ill patients? *Critical Care* 2010, 14:138.